European Primary Care Cardiovascular Society

ASCVD event prevention achieved with guideline-recommended statin therapy varies greatly among different guidelines

Jan. 17, 2018 - Mortensen MB and Nordestgaard BG. - Ann Intern Med 2018

Statin eligibility differs substantially in the 5 major guidelines, and this impacts on the potential prevention of ASCVD events, which is a function of the number of eligible persons for statin therapy.

Disinformation provided by the anti-statin lobby should be fiercely counteracted to protect patients

Jan. 4, 2018 - news

Following a TV program on the French-German public network ARTE that denied the proven link between cholesterol levels and CVD, the potential effects of such disinformation are considered.

Primary care-based dietary and lifestyle intervention leads to remission of T2DM

Dec. 11, 2017 - Lean MEJ et al., The Lancet 2017

The randomised DIRECT trial evaluated a practical weight management program. On average, weigh reduced by 10 kg and almost half achieved and maintained remission of T2DM at 12 months after starting the intervention.

Main messages for primary care from the 2016 ESC Guidelines for Cardiovascular Prevention

Dec. 8, 2017 - news

A summary of the main messages for primary care from the guidelines for Cardiovascular Prevention in clinical practice, released in 2016 by the Sixth Joint Task Force (ESC and other societies).

Higher risk of vascular dementia, but not Alzheimer’s disease, in post-MI patients

Dec. 4, 2017 - Sundbøll J et al., Circulation 2017

Patients with a history of MI have a higher risk of vascular dementia, particularly if they additionally have a history of stroke, probably due to common risk factors for both diseases.

ESC/EAS statin eligibility in primary prevention may be expanded to high TG levels

Nov. 29, 2017 - Madsen CM et al., Eur Heart J 2017

In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.

Slow self-reported walking pace could be used for risk stratification

Nov. 22, 2017 - Yates T et al., Eur Heart J 2017

In the UK Biobank, a slow self-reported walking pace was associated with a higher risk of all-cause and CV mortality in women and men, particularly in those with a low BMI.

In the SPRINT trial, presence or absence of staff did not affect observed CVD risk reduction

Nov. 14, 2017 - news

AHA 2017 A post-hoc survey of the SPRINT examined whether the presence or absence of physician or nursing in the BP measurement changed the treatment effect.

CV benefit seen in CANTOS trial explained by response to anti-inflammatory treatment

Nov. 13, 2017 - news

AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP <2 mg/L benefitted from a 25% reduction in MACE, irrespective of the dose of canakinumab.

Omega-3 carboxylic acids can benefit patients with severe hypertriglyceridemia

Nov. 13, 2017 - Stroes ESG et al., J Clin Lipidol 2017

Patients with SHTG treated with OM3-CA 2 g daily had a statistically significant reduction in TG and non-HDL-c concentrations compared with those treated with olive oil 2 g daily.

Rationale and effect of targeting IL-1beta to lower inflammation and thereby CV events

Oct. 31, 2017 - Libby P. J Am Coll Cardiol. 2017

This review summarizes the rationale to specifically target IL-1beta to lower residual inflammatory risk, now shown to be effective in the CANTOS trial. Other potential targets are also discussed.

Early lipid changes ≥5% during psychotropic therapy as a warning sign of future clinically relevant dyslipidemia

Oct. 30, 2017 - Delacrétaz A et al., J Clin Lipidol 2017

These data underscore the importance of prospectively monitoring lipid parameters in all patients starting psychotropic treatment, as these drugs may induce or exacerbate dyslipidemia.